Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae b-inactivated polio and hepatitis B vaccines

Acta Paediatrica, International Journal of Paediatrics

Volumn 88, Issue 5, 1999, Pages 513-520

  Vesikari, T ^a,f   Joensuu, J ^a   Baer, M ^b   Kayhty H ^c   Olander R M ^c   Sormunen, H ^c   Miettinen, A ^b   Ward, R L ^d   Guillot, T ^e  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e Searle European Clinical R and D   (France)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Combined vaccinations; Fever; Pertussis vaccine; Rhesus rotavirus; Rotavirus vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; PENTACOQ; PLACEBO; POLIOMYELITIS VACCINE; SIMIAN ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; PRIORITY JOURNAL; ROTAVIRUS; SEROCONVERSION; VACCINATION;

ANTIBODY FORMATION; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFANT; POLIOVIRUS VACCINE, INACTIVATED; TIME FACTORS; VACCINES, ATTENUATED; VACCINES, COMBINED; VACCINES, CONJUGATE; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 0033059436     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035259950169512     Document Type: Article

References (19)

1. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. Pediatrics 1996; 97: 7-13
2. Pérez-Schael I, Guntinas MJ, Pérez M, Pagone V, Rojas AM, González R, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337: 1181-7
3. Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350: 1205-9
4. Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998; 17: 334-40
5. Dennehy PH, Rodgers GC Jr, Ward RL, Markwick AJ, Mack M, Zito ET, For the US Rhesus Rotavirus vaccine study group. Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. Pediatr Infect Dis J 1996; 15: 1012-8
6. Helwig H, Mertsola J, Harvey D, Nicolopoulos D, Schaack J-C, Sedlak W, on behalf of the Confederation of European Specialists in Paediatrics (CESP). Childhood immunisation in the European Union. Eur J Pediatr 1998; 157: 676-80
7. Ward RL, Bernstein DI, Shukla R, Young EC, Sherwood JR, McNeal MM, et al. Effects of antirotavirus antibody on protection of adults administered a human rotavirus. J Infect Dis 1989; 159: 79-88
8. Knowlton DR, Spector DM, Ward RL. Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods 1991; 33: 127-34
9. Ward RL, Kapikian AZ, Goldberg KM, Knowlton DR, Watson MW, Rappaport R. Serum rotavirus neutralizing antibody titres compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays. J Clin Microbiol 1996; 34: 983-5
10. Kristiansen M, Aggerbeck H, Heron I. Improved ELISA for determination of anti-diphtheria and/or anti-tetanus antitoxin antibodies in sera. APMIS 1997; 105: 843-53
11. Manclark CR, Meade BD, Burstyn D. Serological response to Bordetella pertussis. In Rose NR, Friman H editors. Manual of clinical laboratory immunology, 3rd ed. Washington DC: ASM, 1986
12. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990; 135: 121-8
13. Kurikka S, Käyhty H, Saarinen L, Rönnberg P-R, Eskola J, Mäkelä PH. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. J Infect Dis 1995; 172: 1268-72
14. Käynty H, Mä'kelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. (J Infect Dis 1984; 147: 1100). Reply to the letter of Dr Porter Anderson. J Infect Dis 1984; 149: 1034-5
15. Albrecht P, van Steenis G, van Wezel A. Standardization of poliovirus neutralizing antibody test. Rev Infect Dis 1984; 6: 540-5
16. Markwick AJ, Rennels MB, Zito ET, Wade MS, Mack ME, for the US Rhesus Rotavirus Vaccine Study GroupRev Infect Dis J 1998; 17: 913-8
17. Robinson A, Funnell SGP. Potency testing of acellular pertussis vaccines. Vaccine 1992; 10: 139-41
18. Dagan R, Kassis I, Sarov B. Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates. Pediatr Infect Dis J 1992; 11: 991-6
19. Vesikari T, Joensuu J. Review of rotavirus vaccine trials in Finland. J Infect Dis 1996; 174 Suppl 1: S81-7